Media coverage about Urogen Pharma (NASDAQ:URGN) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Urogen Pharma earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media stories about the company an impact score of 48.2378307190851 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

URGN has been the topic of a number of research reports. UBS Group downgraded shares of Urogen Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 15th. Ladenburg Thalmann Financial Services initiated coverage on shares of Urogen Pharma in a research report on Tuesday, January 2nd. They set a “buy” rating and a $50.00 target price on the stock. Jefferies Group raised their target price on shares of Urogen Pharma from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Monday, October 9th. Zacks Investment Research raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, October 18th. Finally, CIBC restated an “outperform” rating and issued a $51.00 price target (up from $32.00) on shares of Urogen Pharma in a report on Wednesday, November 15th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $39.00.

How to Become a New Pot Stock Millionaire

Urogen Pharma (NASDAQ URGN) traded down $3.06 during mid-day trading on Monday, reaching $50.78. 153,102 shares of the company were exchanged, compared to its average volume of 171,811. Urogen Pharma has a one year low of $13.01 and a one year high of $56.56.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Tuesday, November 14th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.10). analysts anticipate that Urogen Pharma will post -1.88 earnings per share for the current fiscal year.

In related news, major shareholder Proquest Investments Iv, L.P. sold 209,298 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $40.60, for a total value of $8,497,498.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

WARNING: This article was reported by Marea Informative and is owned by of Marea Informative. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.mareainformativa.com/2018/01/30/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-urogen-pharma-urgn-stock-price-updated-updated-updated.html.

Urogen Pharma Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Insider Buying and Selling by Quarter for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.